Integra Lifesciences (IART) EVP reports major RSU grant and vesting

Rhea-AI Filing Summary

INTEGRA LIFESCIENCES executive Harvinder Singh, EVP & President, International, reported compensation-related equity activity. On March 11, 2026, he received a grant of 60,865 restricted stock units, which will vest 33%, 33% and 34% on the first, second and third anniversaries of the March 11, 2026 grant date.

Several earlier restricted stock unit awards vested on their second and third anniversaries, leading to the conversion of 20,138 units into common stock over March 10–11, 2026. To cover tax obligations, a total of 6,652 common shares were withheld at prices of $9.55 and $9.61 per share.

After these transactions, Singh directly holds 21,690 shares of common stock. The filing reflects routine vesting and tax withholding rather than open-market buying or selling.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Singh Harvinder

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & PRESIDENT, INTERNATIONAL

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		M		1,216	A	$0	23,152	D
Common Stock	03/10/2026		F		601	D	$9.55	22,551	D
Common Stock	03/11/2026		F		861	D	$9.61	21,690	D
Common Stock	03/11/2026		M		18,922	A	$0	40,612	D
Common Stock	03/11/2026		F		5,190	D	$9.61	35,422	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/10/2026		M			1,216	(1)	(1)	Common Stock	1,216	$0	21,350	D
Restricted Stock Units	$0	03/11/2026		M			2,356	(2)	(2)	Common Stock	2,356	$0	18,994	D
Restricted Stock Units	$0	03/11/2026		M			16,566	(3)	(3)	Common Stock	16,566	$0	2,428	D
Restricted Stock Units	$0	03/11/2026		A		60,865		(4)	(4)	Common Stock	60,865	$0	63,293	D

Explanation of Responses:

1. The award was a restricted stock unit award of which 34% vested on the third anniversary of the grant date of 3/10/2023

2. The award was a restricted stock unit award of which 33% vested on the second anniversary of the grant date of 3/11/2024

3. The award was a restricted stock unit award of which 100% vested on the second anniversary of the grant date of 3/11/2024

4. The award was a restricted stock unit award which will vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date of 3/11/2026.

Remarks:

	/s/ Michael D. Hutchinson; Attorney-in-Fact for Harvinder Singh	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Integra Lifesciences (IART) executive Harvinder Singh receive in this Form 4 filing?

Harvinder Singh received a grant of 60,865 restricted stock units as equity compensation. The award vests 33%, 33% and 34% on the first, second and third anniversaries of the March 11, 2026 grant date.

How do the new restricted stock units for IART’s Harvinder Singh vest over time?

The new restricted stock unit award vests in three tranches over three years. Specifically, 33% vests on the first anniversary, 33% on the second, and 34% on the third anniversary of the March 11, 2026 grant date.

Were any Integra Lifesciences (IART) shares sold on the open market in this Form 4?

The Form 4 shows only tax-withholding dispositions, not open-market sales. A total of 6,652 common shares were withheld at $9.55 and $9.61 per share to satisfy tax obligations tied to restricted stock unit vesting.

How many Integra Lifesciences (IART) shares does Harvinder Singh hold after these transactions?

Following the reported transactions, Harvinder Singh directly holds 21,690 shares of Integra Lifesciences common stock. This reflects the net position after restricted stock unit conversions into shares and share withholding for related tax obligations.

What restricted stock units vested for IART’s Harvinder Singh in March 2026?

Several prior restricted stock unit awards reached their second or third vesting anniversaries in March 2026. In total, 20,138 units were converted into common stock as part of this scheduled vesting and derivative exercise activity.

Is the Form 4 activity for Integra Lifesciences (IART) executive Harvinder Singh routine compensation?

The transactions reflect routine equity compensation mechanics. They include a new restricted stock unit grant, scheduled vesting of earlier awards into common stock, and share withholding to cover associated tax liabilities, rather than discretionary market trades.